EUVIMEDAtrasti EUVIMED
CrossrefInformacijos kortelė

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue

Nicole D. Zantek, Caroline R. Alquist, Jan C. Hofmann, Reinhard Klingel, Yosef Levenbrown, Oluwatoyosi A. Onwuemene, Gopal Patidar, Christopher J. Patriquin, Jay S. Raval, Amber P. Sanchez, Jennifer Schneiderman, Yvette C. Tanhehco, Laura Connelly‐Smith

Journal of Clinical Apheresis · 2026-09 · 41 (S2)

DOI: 10.1002/jca.70141 ↗
SantraukaBibliografiniai duomenys

Santrauka

ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating, and categorizing indications for the evidence‐based use of therapeutic apheresis (TA) in human disease. As in recent editions, the Tenth Edition of the JCA Special Issue committee has incorporated systematic review and evidence‐based approaches in the grading of evidence and categorization of apheresis indications to make recommendations on the use of apheresis in a wide variety of diseases and conditions. This edition has largely maintained the general layout and concept of a fact sheet introduced in the Fourth Edition (2007). Each fact sheet succinctly summarizes the evidence for the use of TA in a specific disease entity or medical condition. The Tenth Edition comprises 93 fact sheets and 183 graded and categorized indications. This includes two new fact sheets and several changes to indications, categorization, or grade on existing fact sheets. The Tenth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.

Jūsų darbui tinkamos žinios.

Nuo nemokamos pradžios ir asmeninės literatūros paieškos iki viso Research Suite.

Peržiūrėti tarifus →

Ar įtraukti visi leidėjų pilnieji tekstai?

Ne. Bibliografiniai įrašai, santraukos ir pilnieji tekstai yra skirtingas turinys. Ar pilnasis tekstas prieinamas, priklauso nuo šaltinio, Open Access ir jūsų turimų licencijų. EUVIMED planas nepakeičia papildomų leidėjų teisių.

Peržiūrėti tarifus →